Heidelberg, Germany and Seoul, Korea, July 17, 2024 – Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics company, announced today that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's "FL-091" radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers.

Heidelberg, Germany – July 3, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ²²⁵Ac-FL-020.

Shanghai, China, and Heidelberg, Germany – June 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting.

Heidelberg, Germany – May 30, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical trials of ²²⁵Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Gembloux, Belgium – May 17, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO).